NewAmsterdam Pharma Company N.V.
NASDAQ: NAMSW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael Harvey Davidson Facp.
- Employees
- 68
- Headquarters
- Naarden, Netherlands
- IPO year
- 2021
- Market cap
- $3.5B
- Website
- https://www.newamsterdampharma.com
Loading NAMSW…
Loading profile data…Frequently asked questions about NAMSW
What does NewAmsterdam Pharma Company N.V. (NAMSW) do?
NewAmsterdam Pharma Company N.V. is a biopharmaceutical firm currently in the clinical development phase, committed to enhancing therapeutic options for individuals living with metabolic diseases. The company's primary experimental treatment, obicetrapib, is an innovative, selective agent designed to inhibit Cholesteryl Ester Transfer Protein (C...
Where does NAMSW trade?
NewAmsterdam Pharma Company N.V. (NAMSW) trades on the NASDAQ Capital Market.
What sector is NAMSW in?
NewAmsterdam Pharma Company N.V. (NAMSW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of NewAmsterdam Pharma Company N.V.?
Michael Harvey Davidson Facp. is the chief executive officer of NewAmsterdam Pharma Company N.V. (NAMSW).
Where is NewAmsterdam Pharma Company N.V. headquartered?
NewAmsterdam Pharma Company N.V. is headquartered in Netherlands.
Does NAMSW pay a dividend?
NewAmsterdam Pharma Company N.V. (NAMSW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NAMSW go public?
NewAmsterdam Pharma Company N.V. (NAMSW) completed its initial public offering in 2021.